Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis

• Published in: Journal of human hypertension Vol. 27; no. 10; pp. 601 - 611
• Main Authors: Funakoshi, T, Latif, A, Galsky, M D
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.10.2013; Nature Publishing Group
• Subjects: 692/699/67; 692/699/75/243; 692/700/565/1436; 692/700/565/2194; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Blood Pressure - drug effects; Cancer; Cancer patients; Chemotherapy; Chi-Square Distribution; Clinical trials; Drug Administration Schedule; Enzyme inhibitors; Epidemiology; Health Administration; Health aspects; Humans; Hypertension; Hypertension - chemically induced; Hypertension - diagnosis; Hypertension - epidemiology; Hypertension - physiopathology; Immunotherapy; Incidence; Inhibitor drugs; Kidney cancer; Medicine & Public Health; Meta-analysis; Molecular Targeted Therapy - adverse effects; Neoplasms - drug therapy; Neoplasms - enzymology; Niacinamide - administration & dosage; Niacinamide - adverse effects; Niacinamide - analogs & derivatives; Odds Ratio; original-article; Patients; Phenylurea Compounds - administration & dosage; Phenylurea Compounds - adverse effects; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Public Health; Renal cell carcinoma; Risk Factors; Severity of Illness Index; Sorafenib; Targeted cancer therapy; Terminology; Time Factors; meta-analysis; cancer; sorafenib; hypertension

Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databas...